title: Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys.
abstract: Raloxifene has been shown to have estrogen agonist effects on bone and cholesterol metabolism while having estrogen antagonist effects on mammary gland and uterus. Reported here are the results of a study to determine whether raloxifene had the estrogen agonist effect of inhibiting coronary artery atherogenesis and to compare its effects with those of traditional conjugated equine estrogens (CEE) treatment. Ovariectomized (surgically postmenopausal) cynomolgus monkeys were fed a moderately atherogenic diet and treated with a placebo, raloxifene (1 mg/kg x day), raloxifene (5 mg/kg x day), or CEE (Premarin) at a dose that mimicked that of 0.625 mg/day in women. The effects of raloxifene on plasma lipid concentrations were generally comparable to those reported in postmenopausal women treated with raloxifene: reductions in low density lipoprotein cholesterol concentrations and no significant effects on high density lipoprotein cholesterol. We found no evidence that raloxifene had an estrogen agonist effect on coronary arteries. Treatment with CEE resulted in about a 70% reduction in coronary artery plaque size relative to that in the placebo group, whereas neither the low nor the high dose of raloxifene had an effect on coronary artery plaque size. The low dose raloxifene group had about 2 times more atherosclerosis and the high dose group had about 3 times more atherosclerosis than the CEE group.
authors.affiliation: Comparative Medicine Clinical Research Center, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina 27157, USA. tclarkson@cpm.bgsm.edu
authors.forename: T B
authors.initials: TB
authors.lastname: Clarkson
authors.forename: M S
authors.initials: MS
authors.lastname: Anthony
authors.forename: C P
authors.initials: CP
authors.lastname: Jerome
mesh_terms: D000818:Animals; D003324:Coronary Artery Disease / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D003331:Coronary Vessels / Q000187:drug effects / Q000473:pathology; D004036:Diet, Atherogenic; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000819:agonists* / Q000494:pharmacology; D005260:Female; D006736:Horses; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008252:Macaca fascicularis; D009994:Osmolar Concentration; D010052:Ovariectomy; D010880:Piperidines / Q000494:pharmacology*; D017698:Postmenopause / Q000502:physiology*; D020849:Raloxifene Hydrochloride
chemical_list: D004967:Estrogens; D008055:Lipids; D008074:Lipoproteins; D010880:Piperidines; D020849:Raloxifene Hydrochloride; D004958:Estradiol